The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The United States hospital acquired disease testing market is currently witnessing strong growth. Hospital-acquired diseases (HADs) are infections acquired during hospital visits or stays. They are commonly known as nosocomial infections and are caused by bacterial, fungal and viral pathogens. Some of the commonly used HAD testing techniques include the complete blood count (CBC) test, erythrocyte sedimentation rate (ESR) test, urinalysis and analysis of the infected area, blood, urine and other body fluids. These techniques assist in the diagnosis of conditions such as urinary tract infections (UTI), surgical site infections (SSI) and hospital-acquired pneumonia (HAP).
The increasing prevalence of hospital acquired infections (HAIs) and diseases in the United States is one of the key factors driving the growth of the market. Furthermore, the increasing awareness regarding the benefits of the early detection of these diseases is providing a boost to the market growth. Healthcare providers are also emphasizing on maintaining adequate hygiene in hospitals, clinics and other healthcare centers to minimize the risks of HADs. Additionally, various technological innovations, such as the development of microarrays, polymerase chain reaction (PCR), solid phase hybridization and real-time location systems (RTLSs) for preventing and monitoring HAIs, are contributing to the market growth. Looking forward, IMARC Group expects the market to continue its strong growth during 2021-2026.
IMARC Group provides an analysis of the key trends in each sub-segment of the United States hospital acquired disease testing market report, along with forecasts for growth at the region level from 2021-2026. Our report has categorized the market based on region and indication.
Breakup by Indication:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at